Showing 3631-3640 of 6039 results for "".
- Differin Celebrates Retinoid Awareness Week with Educational Initiativeshttps://practicaldermatology.com/news/differin-celebrates-retinoid-awareness-week-with-educational-initiatives/2460710/Following the FDA approval of Differin Gel to be sold over the-counter in 2016, Galderma embarked on a journey to educate consumers about retinoids like adapalene. In 2017, Differin launched its first ever Retinoid Education Week to continue to drive awareness. Now in its fourth year, D
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with n
- Potential Psoriasis Breakthrough: Bimekizumab Performs Well in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/potential-psoriasis-breakthrough-bimekizumab-performs-well-in-moderate-to-severe-plaque-psoriasis/2460684/Two new Phase 3 studies show that bimekizumab-treated psoriasis patients achieved superior levels of skin clearance compared to those who received placebo or ustekinumab. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified
- Second-Draw PPP Loans: What Dermatologists Should Knowhttps://practicaldermatology.com/news/second-draw-ppp-loans-what-dermatologists-should-know/2460680/By Mark Schmidt, CEO, Fund-Ex Solutions Group Dermatologists have proven their resiliency throughout the pandemic, and now more help is here with another round of funding through the Paycheck Protection Program (PPP). The Economic Aid Act reopened the Small Business Administratio
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Breaking News: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://practicaldermatology.com/news/breaking-news-abbvies-allergan-wins-trade-secret-case-against-evolus/2460635/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- AbbVie’s Rinvoq Performs Well in Head-to-Head Phase 3b AD Studyhttps://practicaldermatology.com/news/abbvies-rinvoq-performs-well-in-head-to-head-phase3b-ad-study/2460630/Topline results from the phase 3b “Heads Up” study show that a greater proportion of subjects treated with AbbVie’s Rinvoq (upadacitinib 30mg, once daily) achieved at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, compared to dupilumab (30
- Olay Body Teams Up with Olympic Snowboarder Jamie Anderson to Reduce Winter Skin Drynesshttps://practicaldermatology.com/news/olay-body-teams-up-with-olympic-snowboarder-jamie-anderson-to-reduce-winter-skin-dryness/2460626/Olay Body is teaming up with professional snowboarder and 2X Olympic gold medalist, Jamie Anderson, to give women the tools they need to combat the snow and freezing temperatures that take a toll on skin. Olay Body also joined forces with Oro Valley, Ariz-based dermatologist Sheil
- Revlon Names Martine Williamson As Chief Marketing Officerhttps://practicaldermatology.com/news/revlon-names-martine-williamson-as-its-chief-marketing-officer/2460625/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join